May 18, 2026 — Abbisko Therapeutics (HKEX: 02256) announced that five latest clinical research updates for three of its independently developed innovative oral small-molecule drugs have been selected for the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. These include the CSF-1R inhibitor ABSK021 (pimicotinib), PD-L1 inhibitor ABSK043, and FGFR2/3 inhibitor ABSK061.

The 2026 ASCO Annual Meeting will be held in Chicago, USA, from May 29 to June 2. As one of the world's most influential academic conferences in oncology, this year's meeting will gather the latest clinical research results and frontier treatment advancements in the global oncology field.

Abbisko will present the following research advancements at the ASCO Annual Meeting:

• Title: Effect of pimicotinib on tumor response and physical function (PF) by tumor location in patients with tenosynovial giant cell tumor (TGCT): Results from the phase 3 MANEUVER trial

• Abstract #: 11567

• Session type: Poster Session

• Time: June 1, 2026, 1:30 - 4:30 PM CDT

• Location: Hall A - Posters and Exhibits, Poster Bd 357

• Title: Longer-term safety of pimicotinib in tenosynovial giant cell tumor (TGCT): Integrated analysis of phase 1 and phase 3 MANEUVER trial data

• Abstract #: 11568

• Session type: Poster Session

• Time: June 1, 2026, 1:30 - 4:30 PM CDT

• Location: Hall A - Posters and Exhibits, Poster Bd 358

• Title: Adverse events and their management in patients with tenosynovial giant cell tumor (TGCT) treated with pimicotinib, after longer-term follow-up from the global phase 3 MANEUVER trial

• Abstract #: 11571

• Session type: Poster Session

• Time: June 1, 2026, 1:30 - 4:30 PM CDT

• Location: Hall A - Posters and Exhibits, Poster Bd 361

• Title: Investigator-initiated phase II trial of ABSK043, an oral PD-L1 inhibitor, in patients with angiogenic sarcoma

• Abstract #: TPS11593

• Session type: Poster Session

• Time: June 1, 2026, 1:30 - 4:30 PM CDT

• Location: Hall A - Posters and Exhibits, Poster Bd 379b

• Title: Phase II study of ABSK061 (selective FGFR2/3 inhibitor) combined with ABSK043 (oral PD-L1 inhibitor) ± CAPOX in advanced FGFR2-positive gastric cancer and gastroesophageal junction cancer (GC/GEJC): Preliminary results from ABSK061-201

• Abstract #: e16036

• Session type: Publication Only

About Abbisko Therapeutics

Founded in April 2016, Abbisko Therapeutics Co., Ltd. (HKEX: 02256.HK), is an oncology-focused biopharmaceutical company based in Shanghai that is dedicated to the discovery and development of innovative medicines to treat unmet medical needs in China and globally. The Company was established by a group of seasoned drug hunters with rich research & development and managerial expertise from top multinational pharmaceutical companies. Since its founding, Abbisko Therapeutics has built an extensive pipeline of innovative programs focused on precision oncology and immuno-oncology.

Please visit www.abbisko.com for more information.